The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).
Dong-Wan Kim
No relevant relationships to disclose
Dae Ho Lee
No relevant relationships to disclose
Jin Hyoung Kang
No relevant relationships to disclose
Keunchil Park
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim (U); Clovis; Lilly; Roche
Research Funding - AstraZeneca
Ji-Youn Han
No relevant relationships to disclose
Jong-Seok Lee
No relevant relationships to disclose
In-Jin Jang
Research Funding - Hanmi
Hyo-Yeon Kim
No relevant relationships to disclose
Jeewoong Son
No relevant relationships to disclose
Joo-Hang Kim
Research Funding - Hanmi; Lilly; Pfizer; Roche